Nichi-Iko and Eisai devise Japan alliance
Nichi-Iko is set to obtain by 1 April next year all shares in Eisai’s Elmed Eisai value-added generic pharmaceuticals business in Japan, while Nichi-Iko and Elmed Eisai also plan to “integrate their strengths” and co-promote one another’s generic products in the country, as part of a broader, three-part, strategic alliance agreement.
You may also be interested in...
Despite seeing sales through its US Sagent unit hit by supply issues with CMOs, Nichi-Iko says its US profits have increased on the back of newly-launched products. However, this failed to offset the impact of NHI price revisions in Japan, dragging down profits in the first nine months of the year.
Nichi-Iko and Eisai have announced plans to build on their Japanese generics collaboration by expanding the partnership into China.
Sandoz’ operation in Egypt has banded together with the Egyptian Cancer Society to introduce the firm’s biosimilar to Roche’s Rituxan/MabThera, three years after Hikma in-licensed a rituximab biosimilar from Celltrion.